• Bulletin of the Korean Chemical Society
• /
• 제19권6호
• /
• pp.654-660
• /
• 1998

$[Fe^{II}Fe^{III}BPLMP(OAc)_2](BPh_4)_2$ (1), a new model for the reduced form of the purple acid phosphatases, has been synthesized by using a dinucleating ligand, 2,6-bis[((2-pyridylmethyl)(6-methyl-2-pyridylmethyl)amino) methyl]-4-methylphenol (HBPLMP). Complex I has been characterized by X-ray diffraction method as having (μ-phenoxo)bis(acetato)diiron core. Complex 1 was crystallized in the monoclinic space group C2/c with the following cell parameters: a=41.620(6) Å, b=14.020(3) Å, c=27.007(4) Å, β=90.60(2)°, and Z=8. The iron centers in the complex 1 are ordered as indicated by the difference in the Fe-O bond lengths which match well with typical $Fe^{III}-O\; and\; Fe^{II}-O$ bond lengths. Complex 1 has been studied by electronic spectral, NMR, EPR, SQUID, and electochemical methods. Complex 1 exhibits strong bands at 592 nm, 1380 nm in $CH_3CN$ (ε = 1.0 × 103 , 3.0 × 102). These are assigned to $phenolate-to-Fe^{III}$ and intervalence charge-transfer transitions, respectively. Its NMR spectrum exhibits sharp isotropically shifted resonances, which number half of those expected for a valence-trapped species, indicating that electron transfer between $Fe^{II}\;and\;Fe^{III}$ centers is faster than NMR time scale. This complex undergoes quasireversible one-electron redox processes. The $Fe^{III}_2/Fe^{II}Fe^{III}\;and\;Fe^{II}Fe^{III}/Fe^{II}_2$ redox couples are at 0.655 and -0.085 V vs SCE, respectively. It has $K_{comp}=3.3{\times}10^{12}$ representing that BPLMP/bis(acetate) ligand combination stabilizes a mixed-valence $Fe^{II}Fe^{III}$ complex in the air. Complex 1 exhibits a broad EPR signal centered near g=1.55 which is a characteristic feature of the antiferromagnetically coupled high-spin $Fe^{II}Fe^{III}$ system $(S_{total}=1/2)$. This is consistent with the magnetic susceptibility study showing the weak antiferromagnetic coupling $(J= - 4.6\;cm^{-1},\; H= - 2JS_1{\cdot}S2)$ between $Fe^{II}\; and \;Fe^{III}$center.

• 대한환경공학회지
• /
• 제29권5호
• /
• pp.564-570
• /
• 2007

본 연구에서는 저전압 및 고전류에 의해 운전되는 수중 전기방전 기술을 이용하여 고농도(70,000 mg/L) 철(III)-에틸렌디아민테트라아세트산(Fe(III)-EDTA) 폐액을 처리하였다. 폐액내의 두 전극사이에 교류전압을 인가하면 폐액이 저항체의 역할을 하므로 전극주변 폐액의 온도가 빠르게 상승하며 동시에 전기화학반응에 의해 물이 분해되어 산소 및 수소 기체가 생성된다. 물의 기화 및 전기분해에 의해 생성된 기체가 전극주변을 감싸게 되면 이 기체층에서 강력한 전기방전이 일어난다. 과산화수소의 주입이 없을 때는 전기방전에 의해 약 50%의 Fe(III)-EDTA가 제거되었으며, 과산화수소 주입량이 증가됨에 따라 Fe(III)-EDTA 제거효율이 크게 증가하였다. 초기 Fe(III)-EDTA에 대한 과산화수소의 몰비가 24.7 이상일 때는 1 kWh의 에너지로 80 g 이상의 Fe(III)-EDTA를 제거할 수 있었다. 텅스텐 전극과 철전극을 비교한 결과 전극재질이 Fe(III)-EDTA 제거효율에 미치는 영향은 거의 없는 것으로 나타났다. 본 연구의 공정에서는 초기 Fe(III)-EDTA에 대한 과산화수소의 몰비가 24.7 이상일 때 30분 이내에 Fe(III)-EDTA 제거반응이 완료되었다.

• Journal of Interdisciplinary Genomics
• /
• 제2권2호
• /
• pp.20-25
• /
• 2020

Mucopolysaccharidosis type III (MPS III or Sanfilippo syndrome) is a multisystem lysosomal storage disease that is inherited in an autosomal recessive manner. It consists of four subtypes (MPS IIIA, B, C, and D), each characterized by the deficiency of different enzymes that catalyze the metabolism of the glycosaminoglycan heparan sulfate at the lysosomal level. The typical clinical manifestation of MPS III includes progressive central nervous system (CNS) degeneration with accompanying systemic manifestations. Disease onset is typically before the age of ten years and death usually occurs in the second or third decade due to neurological regression or respiratory tract infections. However, there is currently no treatment for CNS symptoms in patients with MPS III. Invasive and non-invasive techniques that allow drugs to pass through the blood brain barrier and reach the CNS are being tested and have proven effective. In addition, the application of genistein treatment as a substrate reduction therapy is in progress.

• 대한기계학회논문집
• /
• 제19권4호
• /
• pp.941-949
• /
• 1995

An efficient method based on analytic solutions is applied to solve anti-plane Mode III crack problems. The analytic technique developed earlier by the present authors for Laplace's equation in a simply-connected region is now extended to general Mode III crack problems. Unlike typical numerical methods which require fine meshing near crack tips, the present method divides the cracked bodies, typically non-convex or multiply-connected, into only a few super elements. In each super element, an element stiffness matrix, relating the series coefficients of the traction and displacement, is first formed. Then an assembly algorithm similar to that used in the finite elements, is first formed. Then an assembly algorithm similar to that used in the finite elements, is developed. A big advantage of the present method is that only the boundary conditions are to be satisfied in the solution procedure due to the use of analytic solutions. Several numerical results demonstrate the efficiency and accuracy of the present method.

• 한국심리학회지ㆍ일반
• /
• 제36권1호
• /
• pp.81-107
• /
• 2017

베일리영유아발달검사 제3판(Bayley-III)의 미국 규준이 영유아의 발달수행을 과대추정하고 발달지연율을 과소추정 한다는 논란이 있어서, 본 연구는 발달지연의 고위험군인 미숙아를 대상으로 미국 규준 적용시 Bayley-III의 임상적 유용성을 살펴보고자 하였다. 본 연구는 생후 1개월부터 24개월(교정원령)의 미숙아(재태기간 37주 미만)와 만삭아 93명을 대상으로 Bayley-III와 한국형베일리영유아발달검사 2판(K-BSID-II)을 실시하였다. 연구결과는 다음과 같다. 첫째, 미숙아/만삭아 각 93명을 대상으로 혼합설계 분산분석을 실시한 결과 재태기간(경증미숙아, 중증미숙아, 극중증미숙아, 만삭아)에 따른 Bayley-III의 발달지수 및 척도점수 간에 유의미한 차이가 있었다. 특히 경증미숙아 집단 내에서는 발달영역(인지, 언어, 운동)에 따라 유의미한 차이가 있는 것으로 나타냈다. 둘째, Bayley-III와 K-BSID-II을 모두 실시한 미숙아(n=79)를 대상으로 환산점수 평균 간의 차이를 살펴본 결과, Bayley-III의 발달지수는 K-BSID-II의 발달지수에 비해 유의미하게 높은 것으로 나타났으며 발달지연률은 크게 감소하는 것으로 나타났다. 마지막으로 ROC 분석을 통해 발달지연 변별에 대한 Bayley-III의 민감도와 특이도를 분석하고 Bayley-III의 임상적 절단점을 탐색한 결과, Bayley-III의 하위 척도 모두 우수한 수준의 변별정확도를 나타냈으나, 미국 규준 적용시 절단점은 더 높게 나타났다. 본 연구는 미국 규준을 사용하여 Bayley-III를 임상 현장에 적용할 때 점수 해석의 주의를 알리는 실증적인 자료로서, 한국 규준 마련시 표집 문제와 관련된 논의를 제공하였다.

• Archives of Pharmacal Research
• /
• 제22권3호
• /
• pp.243-248
• /
• 1999

Sialic acids are key determinants for biological processes, such as cell-cell interaction and differentiation. Sialyltransferases contribute to the diversity in carbohydrate structure through their attachment of sialic acid in various terminal positions on glycolipid and glycoprotein (N-linked and O-linked) carbohydrate groups. Gal$\beta$ 1,3(4)GlcNAc $\alpha$2,3-sialyltransferase (ST3Gal III) is involved in the biosynthesis of $sLe^{X}$ and sLe^{a}$ known as selection ligands and tumor-associated carbohydrate structures. The appearance and differential distribution of ST3Gal III mRNA during mice embryogenesis [embryonic (E) days; E9, E11, E13, E15] were investigated by in situ hybridization with digoxigenin-labeled RNA probes coupled with alkaline phosphatase detection. On E9, all tissues were positive for ST3Gal III mRNA expression whereas ST3Gal III mRNA on E11 was not detected throughout all tissues. On E13, ST3GAl III mRNA was expressed in different manner in various tissues. In this stage, ST3Gal III mRNA was positive only in the liver, pancreas and bladder. On E15, specific signal for ST3GAl III was detected in the liver, lung and forebrain. These results indicate that ST3Gal III is differently expressed at developmental stages of mice embryo, and this may be importantly related with regulation of organogenesis in mice.

• 생명과학회지
• /
• 제9권4호
• /
• pp.439-452
• /
• 1999

This study was designed to investigate the effects of sea tangle (Laminaria japonica) extract and fucoidan components on anti-aging action. Sprague-Dawley(SD) male rats (210$\pm$5g) were fed experimental diets Dasi-Ex group: sea tangle extract powder of 4.0% added to control diet; Fuco-I, II and III groups: funcoidan powder of 1, 2 and 3% added to Dasi-Ex group for 45 days. Hydroxyl radical (.OH) formations were significantly inhibited (10-20% and 25-30%) in serum and brain mitochondria of Dasi-Ex and Fuco-I, II and III groups compared with control group. Significant differences in .OH formations of brain mitochondria in Dasi-Ex and Fuco-I groups could not be obtained, but.OH formations of brain microsomes resulted in a significant decrease (15-20%) in Fuco-II and III groups compared with control group. Basal oxygen radical (BOR) formations were significantly decreased about 10% and 13-15% in brain mitochondria of Dasi-Ex and Fuco-I group, and Fuco-II, III groups, and also decreased about 10% and 15-20% in brain microsomes of Dasi-Ex and Fuco-I groups, and Fuco-II, III groups. LPO levels of brain mitochondria and microsomes were significantly inhibited about 10% in Dasi-Ex and Fuco-I, II groups and 15% in Fuco-III groups. Oxidized proteins (>C=O) were significantly inhibited about 10% in serum of Dasi-Ex and Fuco-I, II, III groups and brain mitochondria of Dasi-Ex group, while remarkably inhibited (30~35%) in brain mitochondria of Fuco-I, II and III groups. Nitric oxide (NO) levels were significantly inhibited (12~15%) in serum of Fuco-I, II and III groups, but there no significant difference in serum NO levels of Dasi-Ex group. Superoxide dismutase (SOD) activities were remarkably increased (30~ 60%) in serum of Fuco-I, II and III groups, but there were no significant differences in SOD activities in serum of Dasi-Ex group. Catalase (CAT) activities were significantly increased about 20% in serum of Dasi-Ex and Fuco-I, II, III groups. Mn-SOD activities in brain mitochondria were significantly increased about 17% in Dasi-Ex group, while remarkably increased 26~36% in Fuco-I, II, III groups. Cu,Zn-SOD activities in brain cytosol were dose-dependently of fucoidan increased 10%, 12% and 18%, respectively, compared with control group. These results suggest that anti-aging effects of fucoidan may play a pivotal role in attenuating a various age-related changes such as chronic degenerative disease and senile dementia.

• Korean Chemical Engineering Research
• /
• 제44권5호
• /
• pp.547-554
• /
• 2006

응집공정에서 교반조건과 응집제 주입농도에 따른 알루미늄 가수분해종 변화에 대한 실험결과 다음과 같은 결론을 얻을 수가 있었다. 알루미늄 표준용액을 이용하여 모노머성 알루미늄과 페론 반응을 살펴본 결과 반응초기에 급격한 반응률을 보이며 반응시간 3분 정도에 평형에 도달함을 알 수 있었다. 순수의 경우 교반시간에 따른 영향은 거의 나타나지 않고 있으며 거의 일정한 반응률을 보이고 있었다. 상수원수의 경우 입자상 물질과 유기물의 존재함에 따라 응집제 주입시 수중에서 형성되는 알루미늄 가수분해종이 입자상 물질 및 유기물과 우선적으로 반응하기 때문에 형성되는 알루미늄 가수분해 종에 대한 반응률이 교반시간에 따라 다르게 나타났다. 응집제 주입량이 증가할수록 페론과 반응율이 빠르게 일어나나 일정한 시간이 경과한 후에 반응율을 살펴보면 응집제 주입량이 증가할수록 반응이 느리게 나타났다. 순수의 경우 교반시간에 따른 Ka 값은 교반시간이 증가할수록 Ka 값은 감소함을 알 수 있으며 응집제 주입량의 영향은 크게 나타나지 않고 있다. 그러나 Kb의 경우 응집제 주입량이 증가할수록 반응속도 상수값이 낮아지는 경향을 보이고 있으며, 마찬가지로 교반시간이 증가할수록 Kb 값은 감소함을 알 수 있다. 상수원수를 사용한 경우 순수와 마찬가지로 교반시간에 따른 Ka, Kb값 은 교반시간이 증가할수록 감소하였다. 그러나 응집제 주입량이 증가할수록 Ka 값은 감소하였다.

• 한국제4기학회지
• /
• 제13권1호
• /
• pp.79-89
• /
• 1999

경기만 김포조간대 지층의 제4기 후기 층서를 규명하기 위하여 3공의 심부 시추(기반암까지 시추됨)를 실시하였으며, 퇴적층의 색상과 퇴적구조 및 입도조직에 근거하여 4개의 암상층서단위를 구분하였다. 이러한 암상단위의 층서는 상위에서 하위로 현세(Holocene) 조수퇴적층 (층서단위 I), 초기 현세 담수습지 퇴적층 (층서단위 II), 플라이스토세 후기 조수퇴적층 (층서단위 III) 및 플라이스토세 후기 육상퇴적층 (층서단위 IV)의 순서이다. 특히 단위 III은 지난 최대 빙기 (LGM)동안에 대기중 노출에 따른 풍화 및 결빙의 영향을 받은 상부(층서단위 III-a)와 풍화를 받지 않은 하부(층서단위 III-b)로 세분된다.

• Journal of mucopolysaccharidosis and rare diseases
• /
• 제2권1호
• /
• pp.8-12
• /
• 2016

Mucolipidosis (ML) is a kind of skeletal dysplasia. Characteristic X-ray findings of the bone may contribute to the early diagnosis and treatment of ML II/III. Skeletal radiographs show distinctive patterns at different ages: neonatal hyperparathyroidism, osteodystrophy (similar to chronic osteitis fibrosa cystica), and dysostosis multiplex. Patients with ML II/III show a mixture of osteodystrophic bone changes and atypical changes of dysostosis multiplex: proximal pointing of the metacarpals in the wrist, dysplastic changes in the lower third of the ilia, marked broadening of the ribs becoming oar-shaped, and beaking of the lower thoracic and lumbar vertebrae. In ML II, the osteodystrophy has clinical and radiographic features of neonatal hyperparathyroidism. In some neonatal subjects, chemical hyperparathyroidism is also demonstrated. After transient hyperparathyroidism in newborns, the progressive osteitis fibrosa cystica develops from 3-6 months of age. Patients with ML III show prominent skeletal involvement, particularly the destruction of vertebral bodies and the femoral heads. Intravenous pamidronate treatment is well tolerated, and it can produce clinical effects, with a reduction in bone pain and improvements in mobility in patients with ML III. In this review, the skeletal manifestations of ML II and III are investigated.